Contract Biomanufacturing Services Global Market -Forecast to 2028

Publishing Date : September, 2020
Report Code : HCPH0111
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Biologics manufacturing or Biomanufacturing is primarily a recombinant DNA technology based complex process of manufacturing biopharmaceuticals using engineered or natural living expression platforms like the mammalian and insect cell cultures, unicellular microbials or the multicellular transgenic plants and animals. The biologics manufacturing is a complex process involving huge capital and sound technical expertise. Many large and small biopharmaceutical companies are turning to outsource their bioprocessing or biomanufacturing activities to reduce capital investments, to accelerate the speed to market of their innovative products and to gain a cost-effective and timely access to flexible and scalable, most appropriate biomanufacturing facilities and technologies along with skilled and technical expertise. The outsourcing process enables large pharmaceutical companies to focus on their core competencies while for small companies and virtual start-ups, it is the only way to get their innovative biological products into the market without making huge investments on building the internal manufacturing capabilities. Contract manufacturing organizations, particularly for R&D and clinical trials, are making product manufacturing process more efficient and often less costly. Also, the use of single-use bioreactors is effectively reducing the manufacturing facility cost.

The contract biomanufacturing services global market is expected to reach $57.1 billion by 2028 growing at a low teen CAGR from 2020 to 2028. There is a continued growth of the biopharmaceutical market which is expected to nearly double in the next 10 years. This is attributed to continued new product approvals, expansion of indications for current products, increasing awareness and adoption of these advanced biological products in the less-developed countries and increasing efficient therapeutic products demand from the aging population burdened with various kinds of chronic diseases like cancer, arthritis and genetic diseases in the U.S. and other major pharmaceutical markets. Many blockbuster drugs in the verge of patent expirations is also giving room for many biosimilar (and bio-better) companies to enter into the global biopharmaceuticals market subsequently involving many CROs, CDMOs, and CMOs to enter into the picture to meet the huge volume demand of these biological products. Hence, there is every reason to assume that future growth in biopharmaceutical outsourcing will continue at a minimum of 14% in western countries to about 18% in Asian countries.

Nowadays, CMOs are gaining much prominence to meet the increasing demand for the clinical and commercial supply of biologics. These bioservice providers have become an integral part of the rapidly expanding biopharma industry as they are equipped with the latest technological capabilities and expanded manufacturing capacities. By expanding manufacturing capacities or acquiring new facilities and thus adding novel, advanced and complementary capabilities, increased production capacities and expanded geographical reach to their services portfolio, CDMO’s focus on becoming the single, strategic partner to their customers by providing cost-effective end-to-end biologics development and manufacturing services. In September 2020, Catalent Inc. has invested $130 million for the addition of five additional suites to enhance their late phase clinical to commercial gene therapeutic manufacturing. In August 2020, Samsung Biologics had invested approximately $2 billion to build a fourth Super Plant with an additional 256KL production capacity to offer multi-scale manufacturing services. In January 2020, Cognate BioServices had acquired Cobra Biologics, a leading CDMO specialized in plasmid DNA and viral vector development and manufacturing services to enhance its capabilities in gene therapeutics.

The contract biomanufacturing global market is dominated by North American region which commanded the largest revenue in 2020 and is expected to grow at a low teen CAGR during the forecasted period according to IQ4I estimation. The Asia Pacific region is witnessing huge growth opportunities in terms of biologics outsourcing and many of the local CMOs are leading the way to make the region the most preferred destination for biologics outsourcing. Some of the reasons for countries like China, South Korea and India becoming the favourite destinations for biologic outsourcing projects include the lower labor cost, availability of high technical expertise and huge manufacturing facilities and favorable, supportive government regulations related to contract biomanufacturing in these regions. Asia-Pacific region is the fastest growing region in the contract biomanufacturing global market in 2020 and is expected to grow at high teen CAGR during the forecasted period.

According to IQ4I analysis, even though in-house biomanufacturing capacities still hold a major share of 67.8% in the biomanufacturing market, their capacity utilization rate is less compared to that of CMO’s with a utilization rate of 65.5%. Most of the CMO’s are currently utilizing mammalian culture techniques for the commercial, GMP production of biotherapeutics. Most of the CMO based biomanufacturing capacity is consolidated with major players like Samsung Biologics, Boehringer Ingelheim, Fujifilm and AbbVie. The global medium penetration range of CMO biomanufacturing capacity is expected to increase immensely in the coming years attributed to the vast opportunity in the space and various capacity expansion projects being executed by the CMO’s in response to the elevating biomanufacturing capacity demand.

The global bio-manufacturing outsourcing market is driven by factors such is driven by the increasing trend of outsourcing among the biopharmaceutical companies, availability of advanced bioprocessing capabilities among the contract bioservice providers and the escalating approval and adoption of biologics and the cost effective biosimilars among the value centric global patient pool leading to huge volume demand for biologics. Emergence of advanced biotherapeutics, increasing R&D investments by the biopharma companies, development of precision and orphan indication therapies and the persistently increasing prevalence of chronic, communicable and autoimmune diseases are also boosting contract biomanufacturing market growth. There are certain restraints and threats as well which could potentially hamper the biomanufacturing outsourcing market. These include requirement of huge capital investment for capacity expansion, setting of cGMP compliant facilities and technology up-gradation, need to be compliant with intellectual property protection rights of biopharma companies, development and expansion of in-house biomanufacturing capacities, the trend of low volume biomanufacturing outsourcing and competition from the established and local CDMO’s and stringent regulatory guidelines to be followed during the biomanufacturing.

  • 1     CONTRACT BIOMANUFACTURING SERVICES GLOBAL MARKET
    • 1.1     EXECUTIVE SUMMARY
  • 2     MARKET ANALYSIS
    • 2.1     FACTORS INFLUENCING MARKET
      • 2.1.1     DRIVERS AND OPPORTUNITIES
        • 2.1.1.1     INCREASING TREND OF BIOMANUFACTURING OUTSOURCING
        • 2.1.1.2     ADVANCED BIOPROCESSING CAPABILITIES OF CONTRACT BIOMANUFACTURERS
        • 2.1.1.3     EMERGENCE OF ADVANCED BIOTHERAPEUTICS
        • 2.1.1.4     ESCALATING APPROVALS AND ADOPTION OF BIOLOGICS AND BIOSIMILARS
        • 2.1.1.5     INCREASING R&D EXPENDITURES OF BIOPHARMA COMPANIES
        • 2.1.1.6     INCREASING PREVALENCE OF CHRONIC, AUTOIMMUNE AND COMMUNICABLE DISEASES
        • 2.1.1.7     DEVELOPMENT OF PERSONALIZED AND ORPHAN INDICATION THERAPIES
      • 2.1.2     RESTRAINTS AND THREATS
        • 2.1.2.1     INCREASING FOCUS ON IN-HOUSE BIOLOGICS MANUFACTURING
        • 2.1.2.2     HUGE CAPITAL INVESTMENT FOR CAPACITY AND CAPABILITY EXPANSION
        • 2.1.2.3     COMPLIANCE WITH STRINGENT REGULATORY GUIDELINES
        • 2.1.2.4     COMPLIANCE WITH INTELLECTUAL PROPERTY RIGHTS OF BIOPHARMA COMPANIES
        • 2.1.2.5     COMPETITION AND TREND OF OUTSOURCING OF LOW VOLUME MANUFACTURING
  • 3     CONTRACT BIOMANUFACTURING SERVICES
    • 3.1     INTRODUCTION
    • 3.2     IN HOUSE VS CMO CAPACITY
      • 3.2.1     GLOBAL BIOMANUFACTURING CAPACITY
      • 3.2.2     BIOLOGICS CONTRACT MANUFACTURING ORGANIZATIONS, BY PHASE
    • 3.3     CONTRACT BIOMANUFACTURING, BY PROCESS
      • 3.3.1     BIOMANUFACTURING BY MAMMALIAN CELL CULTURE
      • 3.3.2     MAMMALIAN CELL CULTURE BIOMANUFACTURING V/S MICROBIAL AND OTHER CELL CULTURES
      • 3.3.3     BIOMANUFACTURING BY MICROBIAL CELL CULTURE
        • 3.3.3.1      MICROBIAL CELL CULTURE CMO BIOMANUFACTURING CAPACITY
      • 3.3.4     BIOMANUFACTURING BY OTHER CELL CULTURE
    • 3.4     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BY END USERS
      • 3.4.1     CONTRACT BIOMANUFACTURING OF DIAGNOSTICS
      • 3.4.2     CONTRACT BIOMANUFACTURING OF RESEARCH REAGENTS
      • 3.4.3     CONTRACT BIOMANUFACTURING OF THERAPEUTICS
        • 3.4.3.1     BIOMANUFACTURING OF ANTIBODIES
        • 3.4.3.2     BIOMANUFACTURING OF RECOMBINANT PROTEINS
        • 3.4.3.3     BIOMANUFACTURING OF VACCINES
        • 3.4.3.4     OTHERS (CELL THERAPY AND GENE THERAPY)
    • 3.5     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET, BY REGION
    • 3.6     CONTRACT BIOMANUFACTURING ORGANIZATION CAPACITY PENETRATION
    • 3.7     COMPETITIVE LANDSCAPE
      • 3.7.1     CAPACITY COMPARISON
      • 3.7.2     CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS
      • 3.7.3     COMPANY DEVELOPMENTS
        • 3.7.3.1     AGREEMENT
        • 3.7.3.2     EXPANSION
        • 3.7.3.3     ACQUISITION
        • 3.7.3.4     COLLABORATION AND PARTNERSHIPS
        • 3.7.3.5     PRODUCT LAUNCH
        • 3.7.3.6     FACILITY APPROVALS
        • 3.7.3.7     OTHER DEVELOPMENTS
  • 4     COMPANY PROFILES
    • 4.1     ABBVIE INC. (ABBVIE CONTRACT MANUFACTURING)
      • 4.1.1     OVERVIEW
      • 4.1.2     FINANCIALS
      • 4.1.3     SERVICE PORTFOLIO
      • 4.1.4     KEY DEVELOPMENTS
      • 4.1.5     SWOT ANALYSIS
    • 4.2     ABZENA PLC
      • 4.2.1     OVERVIEW
      • 4.2.2     FINANCIALS
      • 4.2.3     SERVICE PORTFOLIO
      • 4.2.4     KEY DEVELOPMENTS
      • 4.2.5     SWOT ANALYSIS
    • 4.3     AGC INC.
      • 4.3.1     OVERVIEW
      • 4.3.2     FINANCIALS
      • 4.3.3     SERVICE PORTFOLIO
      • 4.3.4     KEY DEVELOPMENTS
      • 4.3.5     SWOT ANALYSIS
    • 4.4     BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 4.4.1     OVERVIEW
      • 4.4.2     FINANCIALS
      • 4.4.3     SERVICE PORTFOLIO
      • 4.4.4     KEY DEVELOPMENTS
      • 4.4.5     SWOT ANALYSIS
    • 4.5     CATALENT INC.
      • 4.5.1     OVERVIEW
      • 4.5.2     FINANCIALS
      • 4.5.3     SERVICE PORTFOLIO
      • 4.5.4     KEY DEVELOPMENTS
      • 4.5.5     SWOT ANALYSIS
    • 4.6     CHARLES RIVER LABORATORIES INTERNATIONAL INC.
      • 4.6.1     OVERVIEW
      • 4.6.2     FINANCIALS
      • 4.6.3     SERVICE PORTFOLIO
      • 4.6.4     KEY DEVELOPMENTS
      • 4.6.5     SWOT ANALYSIS
    • 4.7     COGNATE BIOSERVICES INC. (COBRA BIOLOGICS)
      • 4.7.1     OVERVIEW
      • 4.7.2     FINANCIALS
      • 4.7.3     SERVICE PORTFOLIO
      • 4.7.4     KEY DEVELOPMENTS
      • 4.7.5     SWOT ANALYSIS
    • 4.8     FUJIFILM HOLDINGS CORPORATION (FUJIFILM DIOSYNTH BIOTECHNOL0GIES)
      • 4.8.1     OVERVIEW
      • 4.8.2     FINANCIALS
      • 4.8.3     SERVICE PORTFOLIO
      • 4.8.4     KEY DEVELOPMENTS
      • 4.8.5     SWOT ANALYSIS
    • 4.9     GENSCRIPT BIOTECH CORPORATION
      • 4.9.1     OVERVIEW
      • 4.9.2     FINANCIALS
      • 4.9.3     SERVICE PORTFOLIO
      • 4.9.4     KEY DEVELOPMENTS
      • 4.9.5     SWOT ANALYSIS
    • 4.10     JSR CORPORATION
      • 4.10.1     OVERVIEW
      • 4.10.2     FINANCIALS
      • 4.10.3     SERVICE PORTFOLIO
      • 4.10.4     KEY DEVELOPMENTS
      • 4.10.5     SWOT ANALYSIS
    • 4.11     LONZA GROUP LTD.
      • 4.11.1     OVERVIEW
      • 4.11.2     FINANCIALS
      • 4.11.3     SERVICE PORTFOLIO
      • 4.11.4     KEY DEVELOPMENTS
      • 4.11.5     SWOT ANALYSIS
    • 4.12     MERCK KGAA
      • 4.12.1     OVERVIEW
      • 4.12.2     FINANCIALS
      • 4.12.3     PRODUCT PORTFOLIO
      • 4.12.4     KEY DEVELOPMENTS
      • 4.12.5     SWOT ANALYSIS
    • 4.13     RENTSCHLER BIOPHARMA SE
      • 4.13.1     OVERVIEW
      • 4.13.2     FINANCIALS
      • 4.13.3     SERVICE PORTFOLIO
      • 4.13.4     KEY DEVELOPMENTS
      • 4.13.5     SWOT ANALYSIS
    • 4.14     SAMSUNG BIOLOGICS CO. LTD.
      • 4.14.1     OVERVIEW
      • 4.14.2     FINANCIALS
      • 4.14.3     SERVICE PORTFOLIO
      • 4.14.4     KEY DEVELOPMENTS
      • 4.14.5     SWOT ANALYSIS
    • 4.15     THERMO FISHER SCIENTIFIC INC.
      • 4.15.1     OVERVIEW
      • 4.15.2     FINANCIALS
      • 4.15.3     SERVICE PORTFOLIO
      • 4.15.4     KEY DEVELOPMENTS
      • 4.15.5     SWOT ANALYSIS
    • 4.16     WUXI BIOLOGICS (CAYMAN) INC.
      • 4.16.1     OVERVIEW
      • 4.16.2     FINANCIALS
      • 4.16.3     SERVICE PORTFOLIO
      • 4.16.4     KEY DEVELOPMENTS
      • 4.16.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     CAPACITY COMPARISON OF CONTRACT MANUFACTURING ORGANIZATIONS V’S IN-HOUSE CAPACITIES (L)
      • TABLE 2     BIOLOGICS MANUFACTURED IN MAMMALIAN CELL CULTURE
      • TABLE 3     CONTRACT MANUFACTURING ORGANIZATIONS CAPACITY, BY PROCESS (L)
      • TABLE 4     BIOLOGICS MANUFACTURED IN MICROBIAL CELL CULTURE
      • TABLE 5     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET, BY END USERS, (2019 -2028) ($BN)
      • TABLE 6      SELECTED FDA APPROVED THERAPEUTIC PEPTIDES AND PROTEINS
      • TABLE 7      BIOMANUFACTURING OUTSOURCING GLOBAL MARKET, BY REGION, (2019-2028) ($BN)
      • TABLE 8     AGREEMENT
      • TABLE 9     EXPANSION
      • TABLE 10     ACQUISITION
      • TABLE 11     COLLABORATION AND PARTNERSHIPS
      • TABLE 12     PRODUCT LAUNCH
      • TABLE 13     FACILITY APPROVALS
      • TABLE 14     OTHER DEVELOPMENTS
      • TABLE 15      COMPANY COMPARISON MATRIX, BY MANUFACTURING CAPABILITY
      • Table 16      ABBVIE INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • Table 17      ABBVIE INC.: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 18      ABBVIE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 19      AGC INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 20      AGC INC.: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 21      AGC INC.: CHEMICALS REVENUE, BY SUB-SEGMENTS, (2018-2020) ($MN)
      • TABLE 22      AGC INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 23      BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 24      BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 25      BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 26      CATALENT INC: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 27      CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 28      CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 29     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 30      BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 31     FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLe 32      FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 33      FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 34     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 35      GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2017-2019) ($MN)
      • TABLE 36      GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 37      JSR CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020 (Q1)) ($MN)
      • TABLE 38      JSR CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2018-2020 (Q1)) ($MN)
      • TABLE 39      JSR CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020 (Q1)) ($MN)
      • TABLE 40     LONZA GROUP: TOTAL REVENUE & R&D EXPENSES (2018-2020) ($MN)
      • TABLE 41      LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 42      LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 43     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 44      MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 45      MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 46     SAMSUNG BIOLOGICS CO., LTD: TOTAL REVENUE (2018-2020) ($MN)
      • TABLE 47      SAMSUNG BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 48      SAMSUNG BIOLOGICS: CONTRACT MANUFACTURING REVENUE, BY TYPE (2018-2020) ($MN)
      • TABLE 49      THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 50      THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 51     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY PRODUCT TYPE, (2018-2020) ($MN)
      • TABLE 52     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 53     WUXI BIOLOGICS: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 54      WUXI BIOLOGICS: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • Table 55     WUXI BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)

      LIST OF FIGURES

      • FIGURE 1     MARKET DYNAMICS
      • FIGURE 2     GLOBAL MANUFACTURING CAPACITY, CGMP V’S NON-CGMP, INHOUSE V’S CMO, (2019-2028)
      • FIGURE 3     CAPACITY UTILIZATION OF CONTRACT MANUFACTURING ORGANIZATIONS, BY STAGE (MILLION LITERS) (2018-2028)
      • FIGURE 4     BIOLOGICS CMO GLOBAL MARKET, BY PHASE, (2018-2028) ($BN)
      • FIGURE 5     BIOLOGICS CMO GLOBAL MARKET, BY PROCESS, (2018-2028) ($BN)
      • FIGURE 6     GLOBAL CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (MN L) (2018-2028)
      • FIGURE 7     CMO CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (MN L) (2018-2028)
      • FIGURE 8     BIO-MANUFACTURING OUTSOURCING GLOBAL MARKET, BY END USERS ($BN)
      • FIGURE 9     ADC PIPELINE FOR CANCER (2020)
      • FIGURE 10     MONOCLONAL ANTIBODY PIPELINE FOR NON-CANCER INDICATIONS (2020)
      • FIGURE 11     MONOCLONAL ANTIBODY PIPELINE FOR CANCER (2020)
      • FIGURE 12     OUTLOOK OF BIOLOGICS CMO GLOBAL MARKET SHARE, BY REGION 2020 (%) AND MANUFACTURING IN METRIC TONS, (2019-2028)
      • FIGURE 13     CONTRACT BIOMANUFACTURING CAPACITY PENETRATION (2020)
      • FIGURE 14     CAPACITY COMPARISION OF TOP 15 CONTRACT MANUFACTURING ORGANIZATIONS (L)
      • FIGURE 15     CONTRACT BIOMANUFACTURING SERVICES GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2020 (%)
      • FIGURE 16     KEY DEALS (2019 – 2020)
      • FIGURE 17     OVERVIEW: ABBVIE INC.
      • FIGURE 18     SWOT: ABBVIE CONTRACT MANUFACTURING
      • FIGURE 19     SWOT: ABZENA PLC
      • FIGURE 20     OVERVIEW: AGC INC.
      • FIGURE 21     SWOT: AGC INC.
      • FIGURE 22     OVERVIEW: BOEHRINGER INGELHEIM
      • FIGURE 23     SWOT: BOEHRINGER INGELHEIM
      • FIGURE 24     OVERVIEW: CATALENT INC.
      • FIGURE 25     SWOT: CATALENT INC.
      • FIGURE 26     OVERVIEW: CHARLES RIVER LABORATORIES
      • FIGURE 27     SWOT: CHARLES RIVER LABORATORIES
      • FIGURE 28     SWOT: COGNATE BIOSERVICES INC.
      • FIGURE 29     OVERVIEW: FUJIFILM HOLDING CORPORATION
      • FIGURE 30     SWOT: FUJIFILM HOLDING CORPORATION
      • FIGURE 31     OVERVIEW: GENSCRIPT BIOTECH CORPORATION
      • FIGURE 32     SWOT: GENSCRIPT BIOSCIENCES CORPORATION
      • FIGURE 33     OVERVIEW: JSR CORPORATION
      • FIGURE 34     SWOT: JSR CORPORATION
      • FIGURE 35     OVERVIEW: LONZA GROUP
      • FIGURE 36     SWOT: LONZA GROUP
      • FIGURE 37     OVERVIEW: MERCK KGAA
      • FIGURE 38     SWOT: MERCK KGAA
      • FIGURE 39     SWOT: RENTSCHLER BIOPHARMA
      • FIGURE 40     OVERVIEW: SAMSUNG BIOLOGICS
      • FIGURE 41     SWOT: SAMSUNG BIOLOGICS
      • FIGURE 42     OVERVIEW: THERMO FISHER SCIENTIFIC INC.
      • FIGURE 43     SWOT: THERMO FISHER SCIENTIFIC
      • FIGURE 44     OVERVIEW: WUXI BIOLOGICS
      • FIGURE 45     SWOT: WUXI BIOLOGICS

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     3P Biopharmaceuticals
      • 2     Abbvie Inc. (Abbvie Contract Manufacturing)
      • 3     Abzena PLC
      • 4     Affinity Lifesciences Inc.
      • 5     AGC Inc. (AGC Biologics)
      • 6     Ajinomoto Co. Inc. (Ajinomoto Biopharma services)
      • 7     Albany Molecular Research Inc.
      • 8     Avid Bioservices Inc.
      • 9     Axis Biotech Brasil
      • 10     Batavia Biosciences B.V.
      • 11     Binex Co. Ltd.
      • 12     Biodextris
      • 13     Boehringer Ingelheim International GmbH
      • 14     Catalent Inc.
      • 15     Cevec Pharmaceuticals GmbH
      • 16     Charles River Laboratories International Inc.
      • 17     Cognate Bioservices Inc. (Cobra Biologics)
      • 18     Cytovance Biologics
      • 19     Envigo
      • 20     Europa Bioproducts Ltd.
      • 21     Fapon Biotech Inc.
      • 22     Fujifilm Holdings Corporation
      • 23     Genscript Biotech Corporation
      • 24     GenWay Biotech, Inc.
      • 25     Immunoreagents Inc.
      • 26     JHL biotech Inc.
      • 27     JSR Corporation
      • 28     Kemwell Biopharma
      • 29     Lake Pharma Inc.
      • 30     Lampire Biological Laboratories
      • 31     Lonza Group Ltd.
      • 32     Luina Bio Pty Ltd.
      • 33     Merck KGaA
      • 34     Miltenyi biotec B.V.& Co. KG
      • 35     Northway BiotechPharma
      • 36     Proteogenix
      • 37     Px’Therapeutics
      • 38     Rafa Laboratories Ltd.
      • 39     Rentschler Biopharma SE
      • 40     Samsung Biologics Co. Ltd.
      • 41     Sartorius Group
      • 42     Syngene International Ltd.
      • 43     The Menarini Group (Menarini Biotech s.r.l)
      • 44     Therapure Biopharma Inc.
      • 45     Thermo fisher Scientific Inc.
      • 46     trenzyme GmbH
      • 47     Wacker Chemie AG (Wacker Biotech GmbH)
      • 48     Waisman clinical biomanufacturing
      • 49     WuXi Apptec Co. Ltd.
      • 50     Wuxi Biologics (Cayman) Inc.